CSIMarket
 


Biogen Inc   (BIIB)
Other Ticker:  
 
 

BIIB's Revenue Growth by Quarter and Year

Biogen Inc 's Revenue results by quarter and year




BIIB Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 2,386.30 2,544.00 2,733.80 2,852.60
III Quarter September 2,530.30 2,508.50 2,778.90 3,376.10
II Quarter June 2,456.00 2,589.10 2,775.00 3,681.60
I Quarter March 2,463.00 2,531.80 2,694.00 3,534.30
FY   9,835.60 10,173.40 10,981.70 13,444.60



BIIB Revenue fourth quarter 2023 Y/Y Growth Comment
Biogen Inc reported decrease in Revenue in the fourth quarter 2023 by -6.2% to $ 2,386.30 millions, from the same quarter in 2022.
The decrease in the fourth quarter 2023 Biogen Inc 's Revenue compares unfavorably to the Company's average Revenue growth of 9.26%.

Looking into fourth quarter 2023 results within Biotechnology & Pharmaceuticals industry 5 other companies have achieved higher Revenue growth. While Biogen Inc ' s Revenue decline of -6.2% ranks overall at the positon no. 494 in the fourth quarter 2023.




BIIB Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December -6.2 % -6.94 % -4.16 % -22.3 %
III Quarter September 0.87 % -9.73 % -17.69 % -6.22 %
II Quarter June -5.14 % -6.7 % -24.63 % 1.79 %
I Quarter March -2.72 % -6.02 % -23.78 % 1.28 %
FY   -3.32 % -7.36 % -18.32 % -6.49 %

Financial Statements
Biogen Inc 's fourth quarter 2023 Revenue $ 2,386.30 millions BIIB's Income Statement
Biogen Inc 's fourth quarter 2022 Revenue $ 2,544.00 millions Quarterly BIIB's Income Statement
New: More BIIB's historic Revenue Growth >>


BIIB Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -5.69 % 1.42 % -1.62 % -15.51 %
III Quarter September 3.03 % -3.11 % 0.14 % -8.3 %
II Quarter June -0.28 % 2.26 % 3.01 % 4.17 %
I Quarter March -3.18 % -7.39 % -5.56 % -3.73 %
FY (Year on Year)   -3.32 % -7.36 % -18.32 % -6.49 %




Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #6
Healthcare Sector #53
Overall #494

Revenue Y/Y Growth Statistics
High Average Low
41.42 % 9.26 % -22.17 %
(Sep. 30, 2014)   (Sep 30 2021)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #6
Healthcare Sector #53
Overall #494
Revenue Y/Y Growth Statistics
High Average Low
41.42 % 9.26 % -22.17 %
(Sep. 30, 2014)   (Sep 30 2021)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Biogen Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
80.67 % 3.03 % -15.51 %
(March 31, 2004)  


BIIB's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 Biogen Inc realized decline in Revenue from the previous quarter by -5.69% to $ 2,386.30 millions, from $ 2,530.30 millions achived in the previous quarter.

Even seasonal factors which usually fuel IV. Quarter 2023 results, have not salvage the IV. Quarter for the Biogen Inc , Laura Pérez, Biotechnology & Pharmaceuticals industry contributor pointed out, she mentioned little skepticism conserning Biogen Inc 's perspective.

Within Biotechnology & Pharmaceuticals industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Biogen Inc 's Revenue growth quarter on quarter, overall rank is 574.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #8
Healthcare Sector #64
Overall #574
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #8
Healthcare Sector #64
Overall #574
Revenue Q/Q Growth Statistics
High Average Low
80.67 % 3.03 % -15.51 %
(March 31, 2004)  


BIIB's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 Biogen Inc disclosed decline in Revenue from the third quarter by -5.69% to $ 2,386.30 millions, from $ 2,530.30 millions achived a quarter before.

Even periodic factors which commonly fuel IV. Quarter 2023 Revenue, could not salvage the IV. Quarter for the Biogen Inc , Laura Pérez, Biotechnology & Pharmaceuticals industry contributor pointed out, she mentioned some pessimism conserning Biogen Inc 's perspective and mentioned that average quarter on quarter Revenue growth is at 3.03% for Biogen Inc .

Within Biotechnology & Pharmaceuticals industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Biogen Inc 's Revenue growth quarter on quarter, overall rank is 574.


Biogen Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 9,835.60 $ 9,993.30 $ 9,971.50 $ 10,104.60 $ 10,173.40
Y / Y Revenue Growth (TTM) -3.32 % -3.57 % -6.23 % -6.61 % -7.36 %
Year on Year Revenue Growth Overall Ranking # 571 # 1681 # 141 # 152 # 2182
Seqeuential Revenue Change (TTM) -1.58 % 0.22 % -1.32 % -0.68 % -1.83 %
Seq. Revenue Growth (TTM) Overall Ranking # 494 # 1548 # 2644 # 2665 # 1557




Cumulative Revenue growth Comment
Biogen Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Sep 30 2023. If the fiscal year would end in Dec 31 2023, Biogen Inc 's annual Revenue decline would be -3.32% year on year to $9,836 millions.

In the Healthcare sector 60 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 571, from total ranking in previous quarter at 1681.

Revenue TTM Q/Q Growth Statistics
High Average Low
41.42 %
9.26 %
-22.17 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 6
Healthcare Sector # 61
Overall # 571

Revenue TTM Y/Y Growth Statistics
High Average Low
41.42 %
9.26 %
-22.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 53
S&P 500 # 494
Cumulative Revenue growth Comment
Biogen Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Sep 30 2023. If the fiscal year would end in Dec 31 2023, Biogen Inc 's annual Revenue fall would be -3.32% year on year to $9,836 millions.

In the Healthcare sector 60 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 571, from total ranking in previous quarter at 1681.

Revenue TTM Q/Q Growth Statistics
High Average Low
41.42 %
9.26 %
-22.17 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 6
Healthcare Sector # 61
Overall # 571

Revenue TTM Y/Y Growth Statistics
High Average Low
41.42 %
9.26 %
-22.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 53
S&P 500 # 494




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BIIB's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for BIIB's Competitors
Revenue Growth for Biogen Inc 's Suppliers
Revenue Growth for BIIB's Customers

You may also want to know
BIIB's Annual Growth Rates BIIB's Profitability Ratios BIIB's Asset Turnover Ratio BIIB's Dividend Growth
BIIB's Roe BIIB's Valuation Ratios BIIB's Financial Strength Ratios BIIB's Dividend Payout Ratio
BIIB's Roa BIIB's Inventory Turnover Ratio BIIB's Growth Rates BIIB's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Healthcare Services Group Inc -0.04%$ -0.042 millions
Integra Lifesciences Holdings Corp-0.25%$ -0.247 millions
National Research Corporation-0.37%$ -0.375 millions
The Beauty Health Company-0.63%$ -0.633 millions
3m Company-0.82%$ -0.817 millions
Viatris Inc -1.00%$ -0.998 millions
Quest Diagnostics Inc-1.93%$ -1.929 millions
Koru Medical Systems Inc-2.16%$ -2.161 millions
Envista Holdings Corporation-2.30%$ -2.300 millions
Zynex inc -3.11%$ -3.114 millions
Baxter International Inc -3.55%$ -3.550 millions
Caribou Biosciences Inc -3.63%$ -3.629 millions
Gilead Sciences Inc -3.72%$ -3.722 millions
Lifevantage Corp-3.92%$ -3.921 millions
Avantor Inc -4.02%$ -4.022 millions
Escalon Medical Corp -4.53%$ -4.533 millions
Inovio Pharmaceuticals Inc -4.55%$ -4.553 millions
Optinose Inc -4.76%$ -4.756 millions
Cryoport inc -5.13%$ -5.133 millions
Hookipa Pharma inc -5.38%$ -5.378 millions
Abbvie inc -5.42%$ -5.423 millions
Hologic Inc-5.69%$ -5.688 millions
Encision Inc -6.08%$ -6.083 millions
Biogen Inc -6.20%$ -6.199 millions
Curis Inc -6.62%$ -6.616 millions
Bio rad Laboratories Inc -6.62%$ -6.621 millions
Charles River Laboratories International inc -7.85%$ -7.853 millions
Cara Therapeutics inc -7.88%$ -7.881 millions
Arcus Biosciences Inc -7.89%$ -7.889 millions
Qiagen N v -8.67%$ -8.666 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com